{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-010377","form_type":"8-K","ticker":"GCTK","cik":"0001506983","company_name":"Glucotrack, Inc.","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.532306+00:00","generated_at":"2026-05-21T08:29:46.841702+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Glucotrack Q1 net loss widens to $6.8M; cash $9.1M; on track for CBGM study Q3 2025","bullets":["Net loss $6.8M vs $2.9M YoY; includes $3.4M non-cash derivative liability change.","R&D expense $1.9M (down $0.2M); MG&A $1.6M (up $0.8M on legal/professional fees).","Cash $9.1M at Mar 31, 2025 vs $5.6M at Dec 31, 2024; $6.4M from financing.","First patients in Australian CBGM feasibility study expected Q3 2025; FDA IDE pilot study expected Q4 2025.","First-in-human study met primary endpoint; no device-related serious adverse events."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-010377","json":"https://secwatch.observer/filing/0001641172-25-010377.json","markdown":"https://secwatch.observer/filing/0001641172-25-010377.md","text":"https://secwatch.observer/filing/0001641172-25-010377.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506983/000164117225010377/0001641172-25-010377-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506983/000164117225010377/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T08:29:46.841702+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}